Natixis Advisors
KRYS icon

Natixis Advisors’s Krystal Biotech KRYS Stock Holding History

Natixis Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.07M Buy
13,649
+1,524
+13% +$455K 0.01% 908
2026
Q1 		$3.13M Buy
12,125
+443
+4% +$118K ﹤0.01% 972
2025
Q4 		$2.88M Buy
+11,682
New +$2.46M ﹤0.01% 950

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Natixis Advisors's KRYS Position: Q2 2026 in Review

Natixis Advisors increased its Krystal Biotech (KRYS) stake by 13% in Q2 2026, buying an estimated $455K and bringing the position to 13,649 shares worth $5.07M. The position accounts for 0.01% of the portfolio, ranked #908.

Natixis Advisors first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Natixis Advisors held 13,649 shares of Krystal Biotech worth $5.07M as of Q2 2026.
  • Natixis Advisors bought 1,524 Krystal Biotech shares in Q2 2026, an estimated $455K.
  • Krystal Biotech made up 0.01% of Natixis Advisors's portfolio in Q2 2026, its #908 holding.
  • Natixis Advisors first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.